Management of Cancer-associated Disseminated Intravascular Coagulation: guidance from the SSC of the ISTH.
J Thromb Haemost. 2015 Jan 5;
Authors: Thachil J, Falanga A, Levi M, Liebman H, Nisio MD
Abstract
The pathogenesis of cancer-associated disseminated intravascular coagulation (DIC) is complex and multifactorial. It could present as a spectrum ranging from clinically asymptomatic, but with laboratory markers of coagulation activation, to the extreme cases of therapy-resistant thrombosis or bleeding [1]. In this guidance, we try to address some practical considerations for this clinical scenario. This statement will provide clinicians with guidance on how best to manage DIC in patients with cancer, and offer expert consensus to help decision-making in challenging situations. This article is protected by copyright. All rights reserved.
PMID: 25556711 [PubMed - as supplied by publisher]